Trial record 1 of 1 for:    Siponimod
Previous Study | Return to List | Next Study

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01665144
First received: August 3, 2012
Last updated: May 21, 2014
Last verified: May 2014

August 3, 2012
May 21, 2014
December 2012
March 2017   (final data collection date for primary outcome measure)
The delay in time to confirmed disability progression as measured by EDSS. [ Time Frame: Baseline, every 3 month up to the maximum of 60 months ] [ Designated as safety issue: No ]
Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.
The delay in time to confirmed disability progression as measured by EDSS. [ Time Frame: up to the maximum of 60 months ] [ Designated as safety issue: No ]
Confirmed disability is defined as an Increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.
Complete list of historical versions of study NCT01665144 on ClinicalTrials.gov Archive Site
  • Efficacy of BAF312 relative to placebo in confirmed worsening of 25 foot walk test [ Time Frame: Baseline , every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Delay in time to 3 month confirmed worsening of at least 20% from baseline in the timed 25 foot walk test.
  • Efficacy of BAF312 relative to placebo in reducing the increase in T2 lesion volume [ Time Frame: Baseline, every year up to the maximum of 5 years ] [ Designated as safety issue: No ]
    The reduction of the increase in the T1 lesion volume.
  • The delay in time to confirmed disability progression as measured by EDSS. [ Time Frame: Baseline, every 6 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Confirmed disability is defined as increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.
  • Efficacy of BAF relative to placebo in annualized relapses rate and time to the first relapse [ Time Frame: Baseline every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    BAF312 vs placebo measured by the effect on confirmed relapses rate, the time to the first relapse, and proportion of patient free from relapses.
  • Overall response rate on the MSWS-12. [ Time Frame: Baseline, every 6 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    The overall response of the effect of BAF312 compared to placebo patients on the patient reported outcome form MSWS-12.
  • Effect on inflammatory disease activity and burden of disease as measured by MRI [ Time Frame: Baseline, every 12 month up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Effect of BAF312 relative to placebo on disease activity and burden of disease as measured by Gd-T1 lesion, new/enlarged T2 lesion, and brain atrophy on brain MRI scans.
  • effect on 3-month confirmed disability progression as defined by EDSS in predefined sub-groups [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    effect on confirmed disability progression in pre-defined subgroups, including patients with or without superimposed relapses, rapidly evolving patients with 1.5 point or greater change in EDSS score in 2 years prior to enrollment into the study. Patients with score of 4 or more in MSSS and those who don't meet this criteria.
  • Number of patients with adverse event [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: Yes ]
    Safety analysis will be performed on AE by CTCAE grade, serious AEs and Study drug related AEs and the AEs leading to discontinuation of study drug.
  • Number of patients with abnormal lab tests [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: Yes ]
    Safety analysis will be performed on lab abnormalities will be based on CTCAE grades
  • Efficacy of BAF312 relative to placebo in confirmed worsening of 25 foot walk test [ Time Frame: Baseline , every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Delay in time to 3 month confirmed worsening of at least 20% from baseline in the timed 25 foot walk test.
  • Efficacy of BAF312 relative to placebo in reducing the increase in T2 lesion voluime [ Time Frame: Baseline, every year up to the maximum of 5 years ] [ Designated as safety issue: No ]
    The reduction of the increase in the T1 lesion volumne.
  • The delay in time to confirmed disability progression as measured by EDSS. [ Time Frame: Baseline, every 6 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Confirmed disabilty is defined as increase of score of 1 point in patients with baseline score of 3.0 to 5.0 and 0.5 point increase with baseline score of 5.5 to 6.5.
  • Efficacy of BAF relative to placebo in annualized relapses rate and time to the first relapse [ Time Frame: Baseline every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    BAF312 vs placebo measured by the effect on confirmed relapses rate, the time to the first relapse, and proportion of patient free from relapses.
  • Ovearall response rate on the MSWS-12. [ Time Frame: Baseline, every 6 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    The overall reponse of the effect of BAF312 compared to placebo patients on the patient reported outcome form MSWS-12.
  • Effect on inflammatory disease activity and burden of disease as measured by MRI [ Time Frame: Baseline, every 12 month up to the maximum of 60 months ] [ Designated as safety issue: No ]
    Effect of BAF312 relative to placebo on disease activtiy and burden of disease as measured by Gd-T1 lesion, new/enlarged T2 lesion, and brain atrophy on brain MRI scans.
  • effect on 3-month confirmed disabilty progression as defined by EDSS in predefined sub-groups [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: No ]
    effect on confirmed disabilty progression in pre-defined subgroups, including patients with or without superimposed relaspes, rapidly evolving patients with 1.5 point or greater change in EDSS score in 2 years prior to enrollment into the study. Patients with score of 4 or more in MSSS and those who don't meet this criteria.
  • Number of patients with adverse event [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: Yes ]
    Safety analysis will be performed on AE by CTCAE grade, serious AEs and Study drug related AEs and the AEs leading to discontinuation of study drug.
  • Number of patients with abnormal lab tests [ Time Frame: Baseline, every 3 months up to the maximum of 60 months ] [ Designated as safety issue: Yes ]
    Safety analysis will be performed on lab abnormalities will be based on CTCAE grades
Not Provided
Not Provided
 
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis.

Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Secondary Progressive Multiple Sclerosis
  • Drug: BAF312
    Patients will be randomized to receive BAF312. BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose.
  • Drug: Placebo
    Placebo
  • Experimental: BAF312
    1020 patients will be randomized to receive BAF312 during the trial for a duration of 23 to 42 months with a maximum of 60 months. Patients who meet all inclusion and none of the exclusion criteria will be treated with BAF312 daily.
    Intervention: Drug: BAF312
  • Placebo Comparator: Placebo
    Matching Placebo administered orally.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
1530
March 2017
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prior history of relapsing remitting MS
  • SPMS defined as progressive increase of disability over at least 6 months
  • EDSS score of 3.0 to 6.5
  • No relapse of corticosteroid treatment within 3 months

Exclusion Criteria:

  • Women of child bearing potential must use reliable forms of contraception.
  • Diagnosis of Macular edema during screening period
  • Any medically unstable condition determined by investigator.
  • Unable to undergo MRI scans
  • Hypersensitivity to any study drugs or drugs of similar class Other protocol defined inclusion/exclusion may apply.
Both
18 Years to 60 Years
No
Contact: Novartis Pharmaceuticals 1-888-669-6682
Contact: Novartis Pharmaceuticals
Israel,   United States,   Argentina,   Australia,   Austria,   Belgium,   Bulgaria,   Canada,   China,   Czech Republic,   Egypt,   Estonia,   France,   Germany,   Greece,   Hungary,   Ireland,   United Kingdom,   Italy,   Japan,   Latvia,   Lithuania,   Netherlands,   Poland,   Portugal,   Romania,   Russian Federation,   Slovakia,   Spain,   Sweden,   Switzerland,   Turkey
 
NCT01665144
CBAF312A2304
Not Provided
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP